{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:42:53Z","timestamp":1778989373883,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1053\/j.seminhematol.2009.01.005","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T04:17:47Z","timestamp":1240373867000},"page":"176-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Complications in Multiple Myeloma"],"prefix":"10.1053","volume":"46","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Blade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2009.01.005_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1053\/j.seminhematol.2009.01.005_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib4","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib5","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib6","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3174\/ajnr.A0918","article-title":"Vertebroplasty in multiple myeloma: outcomes in a large patient series","volume":"29","author":"McDonald","year":"2008","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1046\/j.1365-2141.2003.04712.x","article-title":"New insights into the pathophysiology and management of bone disease in multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1358\/dot.2004.40.1.799436","article-title":"Bisphosphonate treatment for multiple myeloma","volume":"40","author":"Terpos","year":"2004","journal-title":"Drugs Today"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib12","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.10-1-52","article-title":"Recommendations for zoledronic acid treatment of patients with bone metastases","volume":"10","author":"Berenson","year":"2005","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib16","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma (MM) treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib19","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.6004\/jnccn.2007.0014","article-title":"Multiple myeloma","volume":"5","author":"Anderson","year":"2007","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib21","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2009.01.005_bib23","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdi818","article-title":"ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma","volume":"16","author":"Harousseau","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib25","first-page":"74","article-title":"Undertreatment of cancer pain: barriers and remedies","volume":"1","author":"Grossman","year":"1993","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib26","series-title":"Cancer pain relief and palliative care: report of a WHO expert panel","year":"1990"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib27","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib28","first-page":"263","article-title":"The management of cancer pain","volume":"44","author":"Cherny","year":"1994","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","article-title":"Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey","volume":"77","author":"Birgegard","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2141.1992.tb06939.x","article-title":"Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production","volume":"82","author":"Beguin","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib31","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.V79.8.1987.1987","article-title":"Effect of inflammatory cytokines on hypoxia-induced erythropoietin production","volume":"79","author":"Faquin","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0609.1990.tb00374.x","article-title":"Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders","volume":"44","author":"Denz","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI116178","article-title":"Increased plasma viscosity as a reason for inappropriate erythropoietin formation","volume":"91","author":"Singh","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib34","article-title":"Perioperative blood transfusions for the recurrence of colorectal cancer","volume":"1","author":"Amato","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"Br J Haematol"},{"issue":"suppl 6","key":"10.1053\/j.seminhematol.2009.01.005_bib36","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminhematol.2006.08.008","article-title":"Iron metabolism and iron supplementation in anemia of cancer","volume":"43","author":"Ludwig","year":"2006","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","article-title":"Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma","volume":"70","author":"Silvestris","year":"1995","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib38","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma","volume":"155","author":"Garton","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib39","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib40","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Epoetin Beta Hematology Study Group: randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Darbepoetin Alfa 20000161 Study efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","article-title":"Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis","volume":"58","author":"Musto","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib44","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.07163.x","article-title":"Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated","volume":"142","author":"Katodritou","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000097464","article-title":"Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma","volume":"117","author":"Baz","year":"2006","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21239","article-title":"Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma","volume":"83","author":"Katodritou","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib50","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib51","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib52","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib53","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib54","first-page":"484","article-title":"Pathogenesis and treatment of myeloma kidney","volume":"124","author":"Sanders","year":"1994","journal-title":"J Lab Clin Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib55","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","article-title":"Patients with multiple myeloma and renal failure requiring long-term dialysis: presenting features, response to therapy and outcome in a series of 20 cases","volume":"91","author":"Torra","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib56","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1046\/j.1523-1755.2001.00941.x","article-title":"Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease","volume":"60","author":"Mezzano","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1523-1755.2003.00781.x","article-title":"Gene transfer of truncated I kappa B alpha prevents tubulointerstitial injury","volume":"63","author":"Takase","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib58","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin D myeloma: presenting features, response to therapy, and survival in a series of 53 patients","volume":"12","author":"Blad\u00e9","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-9343(76)90440-X","article-title":"Manifestations of systemic light-chain deposition","volume":"60","author":"Randall","year":"1976","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0889-8588(05)70417-2","article-title":"Biology and therapy of immunoglobulin deposition diseases","volume":"11","author":"Dhodapkar","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","article-title":"Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high-dose dexamethasone containing regimens and impact of novel agents","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib62","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplantation in multiple myeloma with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib64","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 trial","volume":"22","author":"San Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib66","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib67","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3324\/haematol.11463","article-title":"Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma","volume":"92","author":"Ludwig","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib68","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib69","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","article-title":"Complications of multiple myeloma","volume":"21","author":"Blad\u00e9","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib70","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib71","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib72","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib73","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study","volume":"2","author":"Daragon","year":"1993","journal-title":"Eur J Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib74","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib75","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib76","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib77","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib78","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib79","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2009.01.005_bib80","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/sj.leu.2404843","article-title":"The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma","volume":"21","author":"Terpos","year":"2007","journal-title":"Leukemia"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196309000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:19:32Z","timestamp":1758521972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196309000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0037196309000067"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Complications in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2009.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}